SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results, Meets Expectations

SELLAS Life Sciences Group (NASDAQ:SLS) issued its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05), FiscalAI reports.

SELLAS Life Sciences Group Stock Performance

SLS traded down $0.39 during trading hours on Thursday, reaching $8.03. The company’s stock had a trading volume of 3,824,042 shares, compared to its average volume of 7,847,869. The company’s 50-day moving average is $11.27 and its 200-day moving average is $8.74. SELLAS Life Sciences Group has a 52 week low of $1.39 and a 52 week high of $15.88. The firm has a market cap of $1.62 billion, a PE ratio of -38.24 and a beta of 2.73.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.